Oct 2026· Medicine· Vol 105· 0 citations· 39 references
Medicine
TL;DR
High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance and 12-month eGFR was not significantly different between variability groups, however, 12-month eGFR was not significantly different between variability groups.
Abstract
Tacrolimus is a key immunosuppressant with a narrow therapeutic range in kidney transplantation. Early fluctuations in trough concentrations may influence graft stability, yet the clinical significance of early intrapatient variability remains uncertain. This study aimed to evaluate whether tacrolimus variability during the first posttransplant month is associated with renal function at 12 months. This single-center retrospective cohort study included adult kidney transplant recipients receiving tacrolimus-based immunosuppression between January 2017 and December 2021. Tacrolimus variability was quantified as the absolute difference (Δ, ng/mL) between maximum and minimum trough concentrations during the first 30 days, classified as high (Δ > 8 ng/mL) or low (Δ ≤ 8 ng/mL). Renal function was assessed using eGFR at 1, 3, 6, and 12 months. Statistical analyses applied appropriate parametric and nonparametric tests with a significance level of P < .05. High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance. However, 12-month eGFR was not significantly different between variability groups. In multivariable models, recipient age, donor age, and biopsy-proven graft dysfunction were consistently associated with lower eGFR across follow-up. Male donor sex showed a positive association with eGFR only at 6 months, whereas early tacrolimus variability was not independently associated with eGFR at any time point.
BACKGROUND
Tacrolimus is the cornerstone of immunosuppression in pediatric liver transplantation (LT) but exhibits high pharmacokinetic variability.
OBJECTIVE
This study aimed to identify clinical and laboratory determinants of tacrolimus trough levels (C0) during the initial 14 days posttransplant.
METHODS
This re...
E. Eyduran, Ayşen Durak Aslan, Merve Havan et al.· The Annals of Pharmacotherap...· 0 citations
Investigation of the interplay between early graft function and pharmacogenetics on tacrolimus dose requirements in adult kidney transplant recipients found patients with early graft dysfunction who were CYP3A5 nonexpressers had the highest tacrolimus exposure.
M. S. Zimmerman, A. Pasternak, S. Patil et al.· Pharmacotherapy· 0 citations
BACKGROUND
Tacrolimus, featuring a narrow therapeutic index, is key in post-kidney transplant immunosuppression. Changes in CYP3A enzyme expression may complicate achieving therapeutic tacrolimus concentrations. This study investigated factors contributing to CYP3A phenoconversion.
METHODS
Data from 24 kidney transpl...
B. Nemes, Gyula Erdélyi, Tímea Silye-Cseh et al.· Transplantation Proceedings· 0 citations
Tacrolimus trough concentration (C0) serves as a surrogate for drug exposure, but perioperative factors may disrupt this relationship early post-transplantation. We assessed whether the morning trough concentration (C0) on the day of kidney transplantation (POD0) accurately reflects 12-h tacrolimus exposure compared wi...
Hyeeun Kwon, Jin-Myung Kim, Youngmin Ko et al.· Frontiers in Pharmacology· 0 citations
Background. Kidney transplantation remains the optimal treatment for end-stage renal disease, offering superior survival and quality of life compared with dialysis. However, data from low- and middle-income countries (LMICs), particularly in Africa, remain scarce.
Objective. To assess early post-transplant renal functi...
W. V. van Hougenhouck-Tulleken, O. C. Orluwosu, P. Rheeder et al.· South African Medical Journa...· 0 citations
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de no...
J. Uchida, Shunji Nishide, Y. Takeyama et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.